Solriamfetol may curb OSA-associated excessive daytime sleepiness
By Marilynn Larkin, December 11, 2018
Solriamfetol, an investigational norepinephrine-dopamine reuptake inhibitor, improved excessive daytime sleepiness associated with obstructive sleep apnea (OSA) in a phase 3 trial reported last month in Chest.
Click HERE for the full article on MDLinx. This same article also ran in Reuters Health and MD Alert.
Facebook Comments